血管内皮生长因子受体3：抗血管生成治疗的新靶点？
VEGFR3: a new target for antiangiogenesis therapy?
作者信息
Padera Timothy P, Jain Rakesh K
机构信息
Edwin L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
出版信息
Dev Cell. 2008 Aug;15(2):178-9. doi: 10.1016/j.devcel.2008.07.014.
Abstract
VEGFR-3 signaling plays an important role in developmental, physiological, and pathological angiogenesis and lymphangiogenesis. Tammela et al. in Nature show that VEGFR-3, via Notch regulation, is present on endothelial tip cells and is critical to sprouting angiogenesis.
摘要
血管内皮生长因子受体-3（VEGFR-3）信号传导在发育、生理和病理状态下的血管生成及淋巴管生成过程中发挥着重要作用。塔梅拉等人在《自然》杂志上发表的研究表明，VEGFR-3通过Notch调节作用，存在于内皮尖端细胞上，并且对发芽血管生成至关重要。
相似文献
1
VEGFR3: a new target for antiangiogenesis therapy?
Dev Cell. 2008 Aug;15(2):178-9. doi: 10.1016/j.devcel.2008.07.014.
2
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.
Nat Cell Biol. 2011 Sep 11;13(10):1202-13. doi: 10.1038/ncb2331.
3
Endothelial Ca 2+ oscillations reflect VEGFR signaling-regulated angiogenic capacity in vivo.
Elife. 2015 Nov 20;4:e08817. doi: 10.7554/eLife.08817.
4
VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling.
Circ Res. 2017 Apr 28;120(9):1414-1425. doi: 10.1161/CIRCRESAHA.116.310477. Epub 2017 Mar 15.
5
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Oncotarget. 2015 Jun 20;6(17):14940-52. doi: 10.18632/oncotarget.3613.
6
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16.
7
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
Nature. 2012 Mar 18;484(7392):110-4. doi: 10.1038/nature10908.
8
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.
9
VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis.
Cell Res. 2010 Dec;20(12):1319-31. doi: 10.1038/cr.2010.116. Epub 2010 Aug 10.
10
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.
引用本文的文献
1
Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients.
Cancers (Basel). 2020 May 18;12(5):1275. doi: 10.3390/cancers12051275.
2
Endothelial cells in the innate response to allergens and initiation of atopic asthma.
J Clin Invest. 2018 Jul 2;128(7):3116-3128. doi: 10.1172/JCI97720. Epub 2018 Jun 18.
3
Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
Integr Cancer Ther. 2018 Sep;17(3):582-601. doi: 10.1177/1534735418775828. Epub 2018 May 28.
4
Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia.
Exp Ther Med. 2015 Oct;10(4):1404-1412. doi: 10.3892/etm.2015.2697. Epub 2015 Aug 21.
5
Mechanisms of action of therapeutic antibodies for cancer.
Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23.
6
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.
Nature. 2010 May 27;465(7297):487-91. doi: 10.1038/nature08995. Epub 2010 May 5.
7
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
MAbs. 2010 Mar-Apr;2(2):199-208. doi: 10.4161/mabs.2.2.11304.
8
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.
J Cell Biol. 2010 Jan 11;188(1):115-30. doi: 10.1083/jcb.200903137.
本文引用的文献
1
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Mol Cancer Ther. 2008 Aug;7(8):2272-9. doi: 10.1158/1535-7163.MCT-08-0182. Epub 2008 Aug 6.
2
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.
3
Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells.
Cancer Cell. 2008 Jun;13(6):557-60. doi: 10.1016/j.ccr.2008.04.021.
4
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.
5
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.
Nature. 2007 Feb 15;445(7129):776-80. doi: 10.1038/nature05571. Epub 2007 Jan 28.
6
Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries.
Nature. 2007 Feb 15;445(7129):781-4. doi: 10.1038/nature05577. Epub 2007 Jan 28.
7
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Cancer Res. 2007 Jan 15;67(2):593-9. doi: 10.1158/0008-5472.CAN-06-3567.
8
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021.
9
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Science. 2005 Jan 7;307(5706):58-62. doi: 10.1126/science.1104819.
10
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.
Science. 1998 Oct 30;282(5390):946-9. doi: 10.1126/science.282.5390.946.
Zotero 插件